**Opening soon**

**Correlative**

**UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment *(Nelson)*

**UCI 16-01** (PAINT Cancer)-Pathway Analyses for Individualized Network Therapeutics for Cancer *(Nelson)*

---

**HEAD & NECK CANCER**

---

**Neo-Adjuvant - Nasopharyngeal**

**NRG-HN001** Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) *(Ejadi)*

---

**Neo-Adjuvant - Squamous Cell Carcinoma**

**UCI 16-72** Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck *(Ejadi)*

---

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu
**Opening soon**

UCI 16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Larynx, Lip, Oral Cavity & Pharynx) (Bota)

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Head & Neck Cancer (Bota)

UCI 17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Metastatic**

UCI 16-50 Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics & Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Pts With Advanced Solid Malignancies & Subsequently Comparing AZD9150 & AZD5069 Both as Monotherapy & in Combination With MEDI4736 as Second Line Treatment in Pts With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (Nelson)

UCI 17-57** A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Pembrolizumab Monotherapy or Who Have Failed to Demonstrate an Objective Response After 3 Months of Pembrolizumab Monotherapy (Nangia)

**For 2nd Line**

UCI 17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)